Galera announces updated data from its randomized, multicenter, placebo-controlled trial in patients with pancreatic cancer

Near double the median overall survival observed in patients receiving galera's dismutase mimetic + sbrt versus placebo + sbrt, showing strong therapeutic potential

GRTX Ratings Summary

GRTX Quant Ranking